Currently, after conducting a corporate clinical trial of a tissue-regenerated ligament for anterior cruciate ligament reconstruction of the knee, the company is continuing a pilot study to evaluate the safety of the product. With this financing, the company plans to accelerate its business by preparing for clinical trials and establishing commercial production technology for U.S. expansion.

CoreTissue BioEngineering Raises New Funding of 600 Million Yen
CoreTissue BioEngineering Corporation (headquartered in Tsurumi-ku, Yokohama; Yoji Shirokura, Representative Director; hereinafter "CTBE") has raised a total of approximately 600 million yen in funding.
Two new shareholders, MSIVC2025V Investment Limited Partnership, whose unlimited liability partners are Nippon Ham Corporation and Mitsui Sumitomo Insurance Capital Co.
In addition, additional investments were received from existing shareholders, "Waseda Innovation Fund No.3 Investment Business Partnership" and "Waseda Investment Limited Partnership" with WELL INVESTMENT CORPORATION as unlimited liability partner, "MMA Investment Limited Partnership" with MORE MANAGEMENT CORPORATION as unlimited liability partner, and "NextG Investment Limited Partnership" with KSP Inc. as unlimited liability partner. Ltd. as unlimited liability partner, and "NextG Investment Limited Partnership" with KSP Inc. as unlimited liability partner.
CTBE is continuing a pilot study to evaluate the safety of a tissue-regenerative ligament (CT-ACL001) for use in reconstructive surgery of the anterior cruciate ligament of the knee, after conducting a first-in-human (FIH, the first use of a developed product in patient care) study last December in a corporate clinical trial.
With this financing, the company plans to advance preparations for clinical trials in the U.S. with the aim of developing business in the U.S. and to accelerate its business by obtaining feasibility of mass production technology for commercial production of developed products.
New investor comments

Fumio Maeda, Executive Vice President, Executive Vice President, Nippon Ham Co.
We believe that CTBE's efforts will give new value and role to livestock-derived resources in the form of medical devices, and contribute to the realization of performance, health, and further inspiration for athletes and sports enthusiasts. Nippon Ham has formulated a new R&D strategy, "Proteinnovation," for fiscal 2025, with a policy of focusing on the healthcare/medical and upcycling domains as new businesses.
Through our support to CTBE, we hope to contribute to the development of the sports medicine field through advanced utilization of livestock resources.

Takuya Shimazaki, Manager, Investment Department, Mitsui Sumitomo Insurance Capital Co.
Many people who have experienced an anterior cruciate ligament knee injury have undergone reconstructive surgery using their own tendon. And will their own performance return to pre-injury levels? What will I do if I tear it again? CTBE offers a new option that is a world apart from the conventional methods by applying its proprietary decellularization and sterilization technologies.
We have invested in this project in the hope that the success of the ongoing clinical trials in Japan and the initiatives in North America will help solve the 800,000 patient pains that are estimated to occur annually around the world. We will strive to overcome the obstacles in front of us one by one and realize our big dream of providing medical devices from Japan on a global scale!
About CoreTissue BioEngineering, Inc.
CoreTissue BioEngineering is a medical device startup based in Tsurumi-ku, Yokohama, Japan, that was spun out of Waseda University in 2016.
Using the technology developed by Kiyotaka Iwasaki, Faculty of Science and Engineering, Waseda University, which enables decellularization* of even thick tissues and freeze-drying/sterilization technology that maintains strength and allows easy rehydration, we have commercialized our first pipeline of tissue-regenerative ligaments (medical devices) for use in reconstructive surgery on the anterior cruciate ligament of the knee We are the world's pioneer in this field.

(Note) Decellularization (technology): Technology that removes cellular components, etc. that may cause immune reactions from animal tissues and creates tissues that regenerate their own tissues using them as scaffolds when transplanted into the body.
| name of company | CoreTissue BioEngineering Inc. |
| Establishment | November 2016 |
| Location | 301, Life Science Research Center, 1-1-43 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, Japan |
| representative | Yoji Shirokura |
| Business Overview | Development, manufacturing and sales of medical devices based on decellularization technology |
| uniform resouce locator | https://www.coretissue.com/ |










